報價延遲最少15分鐘:2026/11/05 02:01 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.69 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.23/0.05
|
|
企業價值
217.23M
|
| 資產負債 |
|
每股賬面淨值
0.89
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
52.74M
|
|
每股收益
0.79
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel. |
